These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30780072)

  • 1. Low-dose versus standard-dose intravenous alteplase for octogenerian acute ischemic stroke patients: A multicenter prospective cohort study.
    Chao AC; Han K; Lin SF; Lin RT; Chen CH; Chan L; Lin HJ; Sun Y; Lin YY; Chen PL; Lin SK; Wei CY; Lin YT; Lee JT; Hu HH; Bai CH;
    J Neurol Sci; 2019 Apr; 399():76-81. PubMed ID: 30780072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
    Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
    JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Intravenous Low-Dose Alteplase in Relative Contraindication Patients with Acute Ischemic Stroke.
    Ohta T; Okada K; Fukuda M; Masahira N; Matsuoka T; Tsuno T; Takemura M
    J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):1844-1851. PubMed ID: 29555402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 Hours: A Comparative Effectiveness and Safety Study.
    Kim BJ; Han MK; Park TH; Park SS; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Lee J; Lee SJ; Ko Y; Park JM; Kang K; Cho YJ; Hong KS; Kim JT; Choi JC; Kim DE; Shin DI; Kim WJ; Lee J; Lee JS; Yoon BW; Gorelick PB; Bae HJ
    Stroke; 2015 Sep; 46(9):2541-8. PubMed ID: 26243232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial.
    Chen G; Wang X; Robinson TG; Pikkemaat M; Lindley RI; Zhou S; Ping L; Liu W; Liu L; Chalmers J; Anderson CS;
    J Neurol Sci; 2018 Apr; 387():1-5. PubMed ID: 29571842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of Blood Pressure Lowering and Alteplase Dose in Acute Ischemic Stroke: Results of the Enhanced Control of Hypertension and Thrombolysis Stroke Study.
    Wang X; Song L; Yang J; Sun L; Moullaali TJ; Sandset EC; Delcourt C; Lindley RI; Robinson TG; Minhas JS; Arima H; Chalmers J; Kim JS; Sharma V; Wang JG; Pontes-Neto O; Lavados PM; Olavarría VV; Lee TH; Levi C; Martins SO; Thang NH; Anderson CS;
    Cerebrovasc Dis; 2019; 48(3-6):207-216. PubMed ID: 31812956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Analysis on Low- and Standard-Dose Regimes of Alteplase Thrombolytic Therapy for Acute Ischemic Stroke: Efficacy and Safety.
    Zhao G; Huang T; Zheng M; Cui Y; Liu Y; Cheng Z; Wang Z
    Eur Neurol; 2018; 79(1-2):68-73. PubMed ID: 29241193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
    Anderson CS; Robinson T; Lindley RI; Arima H; Lavados PM; Lee TH; Broderick JP; Chen X; Chen G; Sharma VK; Kim JS; Thang NH; Cao Y; Parsons MW; Levi C; Huang Y; Olavarría VV; Demchuk AM; Bath PM; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Ricci S; Roffe C; Pandian J; Billot L; Woodward M; Li Q; Wang X; Wang J; Chalmers J;
    N Engl J Med; 2016 Jun; 374(24):2313-23. PubMed ID: 27161018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).
    Robinson TG; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Demchuk AM; Donnan GA; Kim JS; Lavados PM; Lee TH; Lindley RI; Martins SCO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Nguyen TH; Wang JG; Woodward M; Chalmers J; Anderson CS;
    Stroke; 2017 Jul; 48(7):1877-1883. PubMed ID: 28619989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke: Secondary Analysis of the ENCHANTED Randomized Clinical Trial.
    Wang X; Robinson TG; Lee TH; Li Q; Arima H; Bath PM; Billot L; Broderick J; Demchuk AM; Donnan G; Kim JS; Lavados P; Lindley RI; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sharma VK; Thang NH; Wang JG; Woodward M; Anderson CS; Chalmers J;
    JAMA Neurol; 2017 Nov; 74(11):1328-1335. PubMed ID: 28973174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).
    Yamaguchi T; Mori E; Minematsu K; Nakagawara J; Hashi K; Saito I; Shinohara Y;
    Stroke; 2006 Jul; 37(7):1810-5. PubMed ID: 16763187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis.
    Carr SJ; Wang X; Olavarria VV; Lavados PM; Rodriguez JA; Kim JS; Lee TH; Lindley RI; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Woodward M; Chalmers J; Anderson CS; Robinson TG;
    Stroke; 2017 Sep; 48(9):2605-2609. PubMed ID: 28739832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke.
    Menon BK; Al-Ajlan FS; Najm M; Puig J; Castellanos M; Dowlatshahi D; Calleja A; Sohn SI; Ahn SH; Poppe A; Mikulik R; Asdaghi N; Field TS; Jin A; Asil T; Boulanger JM; Smith EE; Coutts SB; Barber PA; Bal S; Subramanian S; Mishra S; Trivedi A; Dey S; Eesa M; Sajobi T; Goyal M; Hill MD; Demchuk AM;
    JAMA; 2018 Sep; 320(10):1017-1026. PubMed ID: 30208455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke.
    Kvistad CE; Novotny V; Kurz MW; Rønning OM; Thommessen B; Carlsson M; Waje-Andreassen U; Næss H; Thomassen L; Logallo N
    Stroke; 2019 May; 50(5):1279-1281. PubMed ID: 31009339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting outcome in stroke patients treated with 0.6 mg/kg alteplase: evidence from the Japan Alteplase Clinical Trial (J-ACT).
    Mori E; Minematsu K; Nakagawara J; Yamaguchi T;
    J Stroke Cerebrovasc Dis; 2011 Nov; 20(6):517-22. PubMed ID: 20719535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous Recombinant Tissue Plasminogen Activator Does Not Impact Mortality in Acute Ischemic Stroke at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
    Kumar G; Uhrig D; Fowler S; DeLaney MC; Alexandrov AV
    CNS Drugs; 2015 Aug; 29(8):659-67. PubMed ID: 26251162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Readministration of intravenous alteplase in acute ischemic stroke patients: case series and systematic review.
    Qureshi AI; Malik AA; Freese M; Thompson MJ; Khan AA; Suri MF
    Am J Emerg Med; 2015 Feb; 33(2):307.e1-4. PubMed ID: 25190550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperglycemia predicts unfavorable outcomes in acute ischemic stroke patients treated with intravenous thrombolysis among a Chinese population: A prospective cohort study.
    Lin SF; Chao AC; Hu HH; Lin RT; Chen CH; Chan L; Lin HJ; Sun Y; Lin YY; Chen PL; Lin SK; Sun MH; Wei CY; Lin YT; Lee JT; Bai CH;
    J Neurol Sci; 2018 May; 388():195-202. PubMed ID: 29627022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.